Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2023; 14(3): 159-169
Published online Mar 15, 2023. doi: 10.4239/wjd.v14.i3.159
Carbamylated lipoproteins in diabetes
Damien Denimal
Damien Denimal, Department of Biochemistry, University Hospital of Dijon, Dijon 21079, France
Damien Denimal, INSERM LNC UMR1231, University of Burgundy, Dijon 21078, France
Author contributions: Denimal D contributed to conception and design of the work, performed the research of the literature, drafted the manuscript and prepared the figures.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this review.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Damien Denimal, PharmD, PhD, Assistant Professor, Department of Biochemistry, University Hospital of Dijon, 2 rue Ducoudray, BP 37013, Dijon 21079, France. damien.denimal@u-bourgogne.fr
Received: October 27, 2022
Peer-review started: October 27, 2022
First decision: December 26, 2022
Revised: December 27, 2022
Accepted: February 10, 2023
Article in press: February 10, 2023
Published online: March 15, 2023
Core Tip

Core Tip: There is growing evidence that carbamylation of lipoproteins occurring in diabetes contributes to the pathophysiology of atherosclerosis, and therefore plays a role in the cardiovascular risk. Numerous studies have demonstrated that carbamylated low-density lipoproteins (LDL) is more atherogenic than native LDL, citing, for instance, its role in foam cell formation or ability to damage endothelial function. In addition, carbamylated high-density lipoproteins exhibits reduced antiatherogenic properties, especially in terms of the capacity to induce cholesterol efflux from macrophages and to protect endothelium.